Heberprot-P® · Wound Care · Amputation Prevention
Diabetic Foot Treatment in Cuba
Cuba's Center for Genetic Engineering and Biotechnology (CIGB) developed Heberprot-P, a breakthrough intralesional recombinant human epidermal growth factor (hEGF) therapy for complex diabetic foot ulcers. Used in over 20 countries since 2007, it has helped prevent amputations in thousands of patients who had not responded to conventional wound care.
Diabetic Foot — Treatment Video
Cuba Creates Powerful Medicine Against Diabetic Foot Ulcers (Heberprot-P)
Visual Guide
Understanding diabetic foot care in Cuba
See the specialized facilities and patient-centered care that define our diabetic foot treatment programs.
Specialized Endocrinology care in Cuba
Comprehensive international patient coordination in Havana
Clinical Evidence & Outcomes
The science behind diabetic foot treatment in Cuba
Our clinical programs are grounded in peer-reviewed research and coordinated with Cuba's biotechnology institutions. Individual results vary and are confirmed during personalized evaluation.
Heberprot-P®
Diabetic Foot Ulcers
Intralesional recombinant human epidermal growth factor (EGF), developed by Cuba's Center for Genetic Engineering and Biotechnology (CIGB), has helped prevent amputation in thousands of patients across 20+ countries since 2007. It is indicated for advanced ulcers that have not responded to conventional wound care.
Source: CIGB — Center for Genetic Engineering and Biotechnology
Heberprot-P®
Wagner Grade 3–4 Ulcers
Heberprot-P is registered in over 20 countries and has been administered to more than 100,000 patients worldwide. It is specifically indicated for Wagner grade 3 and 4 diabetic foot ulcers — deep ulcers with abscess, osteomyelitis, or gangrene — where standard treatment has failed.
Source: CIGB — Center for Genetic Engineering and Biotechnology
Comprehensive Wound Care
Multidisciplinary Approach
Heberprot-P is administered as part of a comprehensive program including vascular assessment, infection control, glycemic management, debridement, and offloading. The combination of biotechnology and multidisciplinary wound care gives the best chance of healing in cases where amputation was previously the only option.
Source: SMC Salud — Office of Medical Affairs
Outcomes shown reflect published clinical data and aggregate results. Individual results vary based on diagnosis, disease stage, and overall health, and are confirmed during a personalized medical evaluation. This page is for educational purposes and is not a substitute for professional medical advice.
Your Treatment Pathway
Diabetic Foot Care Pathway
A coordinated, step-by-step pathway from pre-travel preparation through treatment in Cuba and post-departure follow-up.
Initial Inquiry & Records Review
Submit your medical records for expert review by our specialist team. Our international coordinators respond within 24–48 hours with an initial assessment.
- Medical records submission via secure portal
- Case review by specialist medical team
- Initial eligibility assessment
Remote Medical Evaluation
Your case is reviewed by the Cuban medical team. Additional tests or imaging may be requested remotely. A personalized treatment plan is developed and shared with you and your home-country physician.
- Specialist remote consultation
- Additional diagnostics if needed
- Personalized treatment plan issued
Program Issuance & Travel Arrangements
SMC Salud issues your official medical program letter. Our coordinators assist with visa application, flight booking, and accommodation — matched to your treatment program and family needs.
- Medical program letter issued
- Visa application support
- Flight & accommodation arranged
Heberprot-P Treatment Program
Wound evaluation, Wagner grading, vascular assessment, and glycemic control review. Intralesional Heberprot-P injections administered several times per week. Comprehensive wound care, debridement, and infection management.
- Wound evaluation & Wagner grading
- Intralesional Heberprot-P injections
- Comprehensive wound care & infection control
Wound Healing & Monitoring
Regular wound assessment and photographic tracking of healing progress. Diabetes management education and foot-care training for patients and caregivers. Vascular monitoring and offloading strategies.
- Wound healing progress tracking
- Diabetes & foot-care education
- Vascular monitoring & offloading
Discharge, Report & Follow-up
Comprehensive medical report translated into your language. Take-home medication supply provided. Telemedicine follow-up program arranged so your Cuban medical team stays connected after you return home.
- Translated comprehensive medical report
- Take-home medication supply
- Telemedicine follow-up scheduled
Our Comprehensive Approach
Heberprot-P®
Intralesional recombinant human epidermal growth factor (hEGF) injected directly into the wound bed to stimulate healing.
Comprehensive Wound Evaluation
Wagner grading, vascular assessment, glycemic control review, and infection management before treatment.
Multidisciplinary Care
Endocrinologists, wound-care specialists, vascular surgeons, and infectious disease experts collaborate on each case.
Amputation Prevention
Designed for ulcers that have not responded to conventional care, with the goal of avoiding major amputation.
Patient & Family Education
Diabetes management, foot care, and wound-care training for patients and caregivers before discharge.
International Coordination
Medical visa, accommodation, interpretation, and 24/7 support throughout the treatment program.
Diabetic Foot — Treatment & Medication
Treatment Options Available in Cuba
Cuba's Center for Genetic Engineering and Biotechnology (CIGB) developed Heberprot-P®, an intralesional recombinant human epidermal growth factor therapy for complex diabetic foot ulcers that have not responded to conventional wound care. Treatment is combined with comprehensive wound management, vascular assessment, infection control, and glycemic management. Heberprot-P is not a cure, and not every patient will benefit. Treatment suitability is determined after medical evaluation of the ulcer grade, vascular status, and overall health.
Treatment suitability is determined after medical evaluation. No therapeutic outcome is guaranteed, and not every patient will benefit. Each case is reviewed individually by the medical team.
Diabetic Foot — Required Documents
Documents for Medical Evaluation
Providing these documents helps our medical team review your case before you travel. You do not need to send every document to begin — send what you have available.
Medical Diagnosis
Diabetes diagnosis and current status
Ulcer Photographs
Clear images of the wound(s) and surrounding skin
Blood Tests
Recent glucose, HbA1c, and laboratory results
Diabetes Records
Diabetes management history and medications
Previous Treatment Reports
Prior wound care and outcomes
Vascular Reports
Doppler or vascular studies, if available
Clinical Evidence
Patient Safety
Expert Specialists
International Standards
Frequently Asked Questions
Questions from international patients
Heberprot-P is a recombinant human epidermal growth factor (hEGF) administered by intralesional injection directly into the wound bed of complex diabetic foot ulcers. It stimulates cell proliferation and angiogenesis in the wound, promoting granulation and healing in ulcers that have not responded to conventional treatment. It was developed by Cuba's Center for Genetic Engineering and Biotechnology (CIGB).
Find country-specific information, testimonials, and FAQs for your region.
Could This Treatment Be Right for You?
Submit your medical records for review by our medical team. We will assess your case and provide a personalized recommendation. Treatment suitability is determined only after medical evaluation.